Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

In June BB Biotech´s share price declined by 6.8% in CHF whereas the net asset value increased by 2.9% in USD. The Nasdaq Biotech Index lost 0.2% (in USD) in June. In June we saw a number of clinical trial read-outs – both positive and negative – from BB Biotech’s portfolio companies including Vertex, Black Diamond, Mersana, Agios and Scholar Rock.<br />
<br />

BB Biotech Update June 2023

In June BB Biotech´s share price declined by 6.8% in CHF whereas the net asset value increased by 2.9% in USD. The Nasdaq Biotech Index lost 0.2% (in USD) in June. In June we saw a number of clinical trial read-outs – both positive and negative – from BB Biotech’s portfolio companies including Vertex, Black Diamond, Mersana, Agios and Scholar Rock.

11.07.2023 - BB Biotech